BioCentury | Feb 26, 2020
Deals

Bicycle’s bicyclic peptides attract Genentech as first corporate immuno-oncology partner

Bicycle is tapping the value of its bicyclic peptide platform through its first broad partnership in immuno-oncology. Via the early discovery deal with Genentech, Bicycle will receive $30 million up front and is eligible for...
BioCentury | Aug 20, 2019
Clinical News

Aug. 20 Clinical Quick Takes: Oxurion misses in Phase II macular edema study; plus NuCana and Moleculin

Oxurion misses in macular edema trial Oxurion N.V. (Euronext:OXUR) sank €2.39 (43%) to €3.18 after reporting that THR-317 plus Lucentis ranibizumab did not improve mean Best Corrected Visual Acuity (BCVA) at three months, the primary...
BioCentury | Nov 16, 2018
Company News

Oxurion, Beta Therapeutics partner to develop heparanase inhibitors

Oxurion N.V. (Euronext:OXUR) and Beta Therapeutics Pty. Ltd. (Canberra, Australia) partnered to develop heparanase inhibitors to treat retinal disorders, including dry age-related macular degeneration (AMD). Oxurion will have an exclusive option to license the heparanase...
BioCentury | May 4, 2018
Clinical News

ThromboGenics reports Phase I/II data for DME candidate

ThromboGenics N.V. (Euronext:THR) said THR-317 was well tolerated with no dose-limiting toxicities (DLTs) reported in the Phase I/II THR-001 trial to treat diabetic macular edema (DME). The single-blind, European trial enrolled 49 DME patients, including...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Diabetic macular edema (DME) In vitro , mouse and rat studies identified two bicyclic peptide inhibitors of KLKB1 that could help treat DME. Screening of a bicyclic peptide library in KLKB1 binding assays followed by...
BioCentury | Dec 15, 2017
Clinical News

ThromboGenics stops diabetic retinopathy trial due to slow enrollment

ThromboGenics N.V. (Euronext:THR) discontinued enrollment in the Phase II CIRCLE trial evaluating ocriplasmin (THR-409) to treat non-proliferative diabetic retinopathy (NPDR) due to slow recruitment rate, which ThromboGenics CEO Patrik De Haes attributed to "patients being...
BioCentury | Dec 14, 2017
Translation in Brief

STUBbing out thrombosis

Patients with chronic kidney disease are at a higher risk of thrombosis, especially following surgery and dialysis, but are also at a higher risk of bleeding than healthy individuals, making standard antithrombotic therapies dangerous. A...
BioCentury | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

Pfizer Inc. (NYSE:PFE) hired Amrit Ray as global president of Pfizer essential health, R&D, effective Friday. He was SVP of external affairs at Johnson & Johnson (NYSE:JNJ). In his new role, Ray will be responsible...
BioCentury | Oct 20, 2017
Company News

VIB grants Oncurious rights to five preclinical oncology assets

In September, the Flanders Institute for Biotechnology (VIB) (Ghent, Belgium) granted Oncurious N.V. (Leuven, Belgium) exclusive rights to a portfolio of five undisclosed immuno-oncology assets in exchange for an additional stake in Oncurious. The institute...
BioCentury | Sep 14, 2017
Targets & Mechanisms

Platelets YAP at cancer

While elevated platelet levels often signify an underlying malignancy, the molecular mechanisms linking the two are not well understood. Now, a team from MD Anderson has shown a well-known, but barely exploited signaling pathway mediates...
Items per page:
1 - 10 of 302
BioCentury | Feb 26, 2020
Deals

Bicycle’s bicyclic peptides attract Genentech as first corporate immuno-oncology partner

Bicycle is tapping the value of its bicyclic peptide platform through its first broad partnership in immuno-oncology. Via the early discovery deal with Genentech, Bicycle will receive $30 million up front and is eligible for...
BioCentury | Aug 20, 2019
Clinical News

Aug. 20 Clinical Quick Takes: Oxurion misses in Phase II macular edema study; plus NuCana and Moleculin

Oxurion misses in macular edema trial Oxurion N.V. (Euronext:OXUR) sank €2.39 (43%) to €3.18 after reporting that THR-317 plus Lucentis ranibizumab did not improve mean Best Corrected Visual Acuity (BCVA) at three months, the primary...
BioCentury | Nov 16, 2018
Company News

Oxurion, Beta Therapeutics partner to develop heparanase inhibitors

Oxurion N.V. (Euronext:OXUR) and Beta Therapeutics Pty. Ltd. (Canberra, Australia) partnered to develop heparanase inhibitors to treat retinal disorders, including dry age-related macular degeneration (AMD). Oxurion will have an exclusive option to license the heparanase...
BioCentury | May 4, 2018
Clinical News

ThromboGenics reports Phase I/II data for DME candidate

ThromboGenics N.V. (Euronext:THR) said THR-317 was well tolerated with no dose-limiting toxicities (DLTs) reported in the Phase I/II THR-001 trial to treat diabetic macular edema (DME). The single-blind, European trial enrolled 49 DME patients, including...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Diabetic macular edema (DME) In vitro , mouse and rat studies identified two bicyclic peptide inhibitors of KLKB1 that could help treat DME. Screening of a bicyclic peptide library in KLKB1 binding assays followed by...
BioCentury | Dec 15, 2017
Clinical News

ThromboGenics stops diabetic retinopathy trial due to slow enrollment

ThromboGenics N.V. (Euronext:THR) discontinued enrollment in the Phase II CIRCLE trial evaluating ocriplasmin (THR-409) to treat non-proliferative diabetic retinopathy (NPDR) due to slow recruitment rate, which ThromboGenics CEO Patrik De Haes attributed to "patients being...
BioCentury | Dec 14, 2017
Translation in Brief

STUBbing out thrombosis

Patients with chronic kidney disease are at a higher risk of thrombosis, especially following surgery and dialysis, but are also at a higher risk of bleeding than healthy individuals, making standard antithrombotic therapies dangerous. A...
BioCentury | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

Pfizer Inc. (NYSE:PFE) hired Amrit Ray as global president of Pfizer essential health, R&D, effective Friday. He was SVP of external affairs at Johnson & Johnson (NYSE:JNJ). In his new role, Ray will be responsible...
BioCentury | Oct 20, 2017
Company News

VIB grants Oncurious rights to five preclinical oncology assets

In September, the Flanders Institute for Biotechnology (VIB) (Ghent, Belgium) granted Oncurious N.V. (Leuven, Belgium) exclusive rights to a portfolio of five undisclosed immuno-oncology assets in exchange for an additional stake in Oncurious. The institute...
BioCentury | Sep 14, 2017
Targets & Mechanisms

Platelets YAP at cancer

While elevated platelet levels often signify an underlying malignancy, the molecular mechanisms linking the two are not well understood. Now, a team from MD Anderson has shown a well-known, but barely exploited signaling pathway mediates...
Items per page:
1 - 10 of 302